recently found that the dihydroorotate dehydrogenase (DHODH) inhibitor brequinar, once used to treat leukemia by restoring terminal differentiation of leukemic myeloid progenitors, could successfully target MDSCs in a breast cancer model. This evidence concerns the gene DHODH and leukemia.